Results 241 to 250 of about 1,518,423 (359)

Interdiffusion in NiAl,CoAl,FeAl compounds and determination of intrinsic diffusion coefficients by multiple markers method.

, 2000
Yoshihiro Yamazaki, Ryusuke Nakamura, Koichi Takasawa, Yoshiaki Iijima   +3 more
openalex   +2 more sources

Lifelong evolution of autoreactive plasma cell numbers, affinity and anatomical location in arthritic K/BxN mice

Arthritis &Rheumatology, Accepted Article.
Objective The spontaneous K/BxN mouse model of rheumatoid arthritis has been used extensively to study chronic inflammation, contribution of immune cells, and the primordial role of autoreactive antibodies in disease initiation and severity. Only the ubiquitous enzyme glucose‐6‐phosphate isomerase (GPI) is the target of IgG autoantibodies secreted by ...
Thibault Vanhoucke, Carlos Castrillon, Odile Richard‐Le Goff, Angga Perima, Matteo Broketa, Andrew D. Griffiths, Patrick England, François Huetz, Pierre Bruhns   +8 more
wiley   +1 more source

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON). [PDF]

BMC Pulm Med
Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM.   +16 more
europepmc   +1 more source

VARIATION IN DISEASE SEVERITY, ATTR-SPECIFIC DRUG TREATMENT RATES, AND TIME TO TREATMENT IN NEWLY DIAGNOSED TRANSTHYRETIN AMYLOIDOSIS-CARDIOMYOPATHY IN THE MEDICARE FEE-FOR-SERVICE POPULATION

José Nativi-Nicolau, Carol Bazell, Maggie Alston, Mia A. Papas, John Venditto   +4 more
openalex   +1 more source

Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation

Arthritis &Rheumatology, Accepted Article.
Background Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Since mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...
Xuezhi Hong, Yanhua Xiao, Haodong Qi, Shihao Zhu, Tim Filla, Andrea‐Hermina Györfi, Yi‐Nan Li, Meilin Xu, Langxian Zhi, Thuong Trinh‐Minh, Clara Dees, Georg Schett, Jörg H.W. Distler, Alexandru‐Emil Matei   +13 more
wiley   +1 more source

Unmasking EGPA with near fatal diffuse alveolar haemorrhage in severe eosinophilic asthma under treatment with benralizumab: a case report. [PDF]

BMC Pulm Med
Drick N, Kaireit TF, Ruwisch J, Schallhorn S, Bauersachs J, Schenk H, Hoeper MM, Witte T, Seeliger B.   +8 more
europepmc   +1 more source

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

Arthritis &Rheumatology, Accepted Article.
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami, Francesco Pollastri, Angelo Fassio, Filippo Montanari, Anna Piccinelli, Camilla Benini, Emma Pasetto, Carmen Dartizio, Davide Gatti, Maurizio Rossini, Ombretta Viapiana   +10 more
wiley   +1 more source

Financial barriers for medical students attending ophthalmology conferences: an analysis of registration fees. [PDF]

Front Med (Lausanne)
Hutchins D, Berkenstock MK.
europepmc   +1 more source

Corporate Governance Structure and Its Relationship with Audit Fee-Evidence from Malaysian Public Listed Companies

, 2013
Azrul Ihsan Husnin, Anuar Nawawi, Ahmad Saiful Azlin Puteh Salin   +2 more
openalex   +2 more sources

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: the Randomized, Phase 3, TULIP‐SC Study

Arthritis &Rheumatology, Accepted Article.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi, Ian N. Bruce, Eric F. Morand, Richard Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Anca Askanase, Patricia Puzio, Emon Khan, Jenny Wissmar, Michael Song, Catharina Lindholm, The TULIP‐SC investigators   +12 more
wiley   +1 more source